Community-Based Programs—Family Health Centers at NYU Langone | NYU Langone Health
Services provided through Family Health Centers at NYU Langone’s Community-Based Programs address the needs of adults, teens, and children.
Community Development Programs at Family Health Centers at NYU Langone | NYU Langone Health
Community development programs are provided through Family Health Centers at NYU Langone’s Community-Based Programs.
Community Events | NYU Langone Health
NYU Langone’s Pearl I. Barlow Center for Memory Evaluation and Treatment hosts regular educational events throughout the year.
Community Events at NYU Langone Hospital—Long Island | NYU Langone Health
NYU Langone Hospital—Long Island provides educational lectures, parent education classes, and support groups for the Long Island community.
Community Health Needs & Assets Assessment & Community Service Plan | NYU Langone Health
NYU Langone’s Community Health Needs and Assets Assessment and its Community Service Plan support behavior change and disease prevention.
Community Medicine Program—Family Health Centers at NYU Langone | NYU Langone Health
The Community Medicine Program—Family Health Centers at NYU Langone provides healthcare through homeless shelters in New York City.
Community Medicine Program—Family Health Centers at NYU Langone Doctors | NYU Langone Health
Find a doctor at Community Medicine Program—Family Health Centers at NYU Langone.
Community Outreach & Engagement at the Trauma Center at NYU Langone Hospital—Suffolk | NYU Langone Health
The Trauma Center at NYU Langone Hospital—Suffolk offers community outreach programs to educate people about the risk of injury.
Community Outreach & Engagement at Trauma Center at NYU Langone Hospital—Long Island | NYU Langone Health
The community outreach program at the Trauma Center at NYU Langone Hospital—Long Island aims to educate people about the risk of injury.
Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis
CAPTIVA is a two-stage Phase III trial randomizing subjects with stroke attributed to 70-99% intracranial atherosclerotic stenosis (sICAS) to 12 months treatment of:1) ticagrelor (180 mg loading dose, then 90mg twice daily) + aspirin 81 mg / day, or2) low dose rivaroxaban (2.5mg twice daily) + aspirin 81 mg / day, or3) clopidogrel (600mg loading dose, then 75 mg daily) + aspirin 81 mg/day. The primary goal of the trial is to determine if the experimental arm(s) (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of the primary endpoint (ischemic stroke, intracerebral hemorrhage (ICH), or vascular death).